Safety and efficacy of ProtekDuo right ventricular assist device: A systemic review

Abstract

AbstractBackgroundRight ventricular failure is associated with increased morbidity and mortality. The ProtekDuo (Livanova, Uk) is a dual‐lumen cannula that allows for percutaneous right ventricular support and may be connected to a centrifugal blood pump such as the TandemHeart or LifeSparc (Livanova, UK). This systematic review aims to evaluate the safety and efficacy of ProtekDuo right ventricular support and evaluate potential clinical variables that can influence outcomes.MethodsPubMed, MEDLINE, SCOPUS, EMBASE, and the Cochrane Library were systematically searched. Studies meeting inclusion criteria, where ProtekDuo was used as the right ventricular assist device with reported numerical death counts for mortality as outcome measures. The primary endpoints were in‐hospital 30‐day and 1‐year mortality rates. Secondary endpoints included ICU length of stay, conversion rates to surgical RVADs, ProtekDuo wean rates, duration of use of ProtekDuo, and adverse event rates.ResultsOf 49 studies reviewed, 7 met inclusion criteria with study periods between October 2014 and November 2019. ProtekDuo was utilized due to RV failure post‐LVAD insertion in 64.8% (68/105) of patients. In‐hospital mortality, 30‐day mortality, and 1‐year mortality ranged between 9%–46%, 15%–40%, and 19%–40%, respectively. Weaning from ProtekDuo and conversion to surgical RVAD ranged between 24%–91% and 11%–35%, respectively. The ICU stay average ranged from 15.8 to 36 days and ProtekDuo mean support duration ranged from 10.5 to 58 days.ConclusionThe ProtekDuo cannula is increasingly utilized as a right ventricular support device. Despite the sparse retrospective data available with variable patient characteristics and study design, percutaneous RV mechanical support via ProtekDuo cannula is a safe and feasible option.